Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Seasonal and pandemic (A/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens.
Bedognetti D, Ansaldi F, Zanardi E, Durando P, Sertoli MR, Massucco C, Balleari E, Racchi O, Zoppoli G, Orsi A, Alicino C, Icardi G, Marincola FM, Zupo S, Ferrarini M, De Maria A. Bedognetti D, et al. Blood. 2012 Aug 30;120(9):1954-7. doi: 10.1182/blood-2012-06-438689. Blood. 2012. PMID: 22936740 Free PMC article. No abstract available.
Positive regulation of oxidative phosphorylation by nuclear myosin 1 protects cells from metabolic reprogramming and tumorigenesis in mice.
Venit T, Sapkota O, Abdrabou WS, Loganathan P, Pasricha R, Mahmood SR, El Said NH, Sherif S, Thomas S, Abdelrazig S, Amin S, Bedognetti D, Idaghdour Y, Magzoub M, Percipalle P. Venit T, et al. Among authors: bedognetti d. Nat Commun. 2023 Oct 10;14(1):6328. doi: 10.1038/s41467-023-42093-w. Nat Commun. 2023. PMID: 37816864 Free PMC article.
Author Correction: Positive regulation of oxidative phosphorylation by nuclear myosin 1 protects cells from metabolic reprogramming and tumorigenesis in mice.
Venit T, Sapkota O, Abdrabou WS, Loganathan P, Pasricha R, Mahmood SR, El Said NH, Sherif S, Thomas S, Abdelrazig S, Amin S, Bedognetti D, Idaghdour Y, Magzoub M, Percipalle P. Venit T, et al. Among authors: bedognetti d. Nat Commun. 2023 Nov 30;14(1):7878. doi: 10.1038/s41467-023-43936-2. Nat Commun. 2023. PMID: 38036530 Free PMC article. No abstract available.
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR, Di Giacomo AM, Caruso FP, Covre A, Mortarini R, Scala G, Costa MC, Coral S, Fridman WH, Sautès-Fridman C, Brich S, Pruneri G, Simonetti E, Lofiego MF, Tufano R, Bedognetti D, Anichini A, Maio M, Ceccarelli M. Noviello TMR, et al. Among authors: bedognetti d. Nat Commun. 2023 Sep 22;14(1):5914. doi: 10.1038/s41467-023-40994-4. Nat Commun. 2023. PMID: 37739939 Free PMC article. Clinical Trial.
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.
Mogenet A, Finetti P, Denicolai E, Greillier L, Boudou-Rouquette P, Goldwasser F, Lumet G, Ceccarelli M, Birnbaum D, Bedognetti D, Mamessier E, Barlesi F, Bertucci F, Tomasini P. Mogenet A, et al. Among authors: bedognetti d. J Transl Med. 2023 Sep 19;21(1):637. doi: 10.1186/s12967-023-04463-2. J Transl Med. 2023. PMID: 37726776 Free PMC article.
Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era.
Bedognetti D, Zoppoli G, Sertoli MR, Zanardi E, Blandini P, Uccellini L, Boccardo F, Andreoli GB, Ghio R, Racchi O, Ferrarini M, De Maria A. Bedognetti D, et al. Int J Hematol. 2010 Mar;91(2):342-4; author reply 345-6. doi: 10.1007/s12185-010-0522-z. Epub 2010 Feb 27. Int J Hematol. 2010. PMID: 20191334 No abstract available.
137 results